Tag Archives: alternative

IBB Shockwave: Temporary Hiccup Or Start Of The Bear Market?

Summary IBB has corrected from its all time high by up to 30%. Hillary Clinton’s snowball was catched right in the eye of the pharma industry. The scare is partially unjustified. We look on pharma future growth figures and M&A activity that will drive the secular bull market higher. We believe that IBB is a good place to invest in the long term. We mention two recent picks where we expect further share price growth. iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB ) has corrected 30% from its all time high of around $401. Several investors start to ask if we have been in the bubble territory. We discuss in this article the facts why the pharmaceuticals industry will continue in a secular bull market towards 2020. We do have a correction now, but it is not the start of the bear market in our opinion. Let’s discuss this in more details. Chart Analysis The IBB bull market started a quick acceleration in 2012. Looking on the quick rise, it is normal to have a correction. No bull market runs up without any significant corrections. Now as China spends more money on drugs also IBB is more correlated with Shanghai SSE index as compared to 2007-2008. IBB data by YCharts Now that we have touched the famous 30% correction line, could we go lower to touch 50%? Let’s have a closer look on what drives this bull market. Pharma Revenues Total pharmaceutical industry revenues are expected to increase from $1.23 trillion in 2014 to $1.61 trillion in 2018. This corresponds to a growth rate of 6-8% annually. Such a 30% increase in revenues would drive the secular bull market higher. Some leading economies are also liberating their drug prices. In June 2015 the communist party in China decided to remove the price caps on a majority of the drugs. That serves as a step towards a more liberalized drug market. We wonder if they tweeted this news to Hillary Clinton. Hillary Clinton’s initiatives might cut the healthcare spending in the United States and set some drug price caps or limitations. We hope that her initiative would not be too disruptive for the industry – if it would be implemented one day. Increasing amount of regulations, restrictions and taxes is typically pushing the businesses to delocalize. These drug firms might also allocate differently their risk capital and not always in the benefit of the patients. For this reason we think that Hillary Clinton’s initiative would end up to be a good compromise. Speaking of delocalizations, we will surely see a wave of startups in China. Currently most big drug firms have large R&D centers in China and the pool of talent has been growing up rapidly. Belgium is no worse, there the politicians compete in attracting new pharmaceutical businesses in the country with tax breaks and benefits. Should Hillary read the tweet streams from Belgium? We think so because Belgium has the highest concentration of life science employees in the whole world and the highest number of Phase I to Phase III drugs in development per capita. Consequently, that has a huge impact on the nation’s economy. We talk later of one Belgian biotechnology company in particular where we hold a long position. Pharma Expenses A topic that is rarely covered in the press is pharma industry’s expenses, i.e. operational costs. Cutting cost is an excellent and quick way to improve the P&L. Well managed companies might be busy cutting down the purchasing and inventory costs and rationalizing the working processes to be more lean and efficient. Pharma industry is still far behind the traditional industries in this. Recent study shows that in 2014 only 32% of the pharma companies procurement organizations’ executives had a full leadership of their key spend areas. The savings generated were slumping down by 45% from year 2009. The study investigated some 185 pharma sector companies with an average revenue of $15 billion. 41% of the companies were based in the U.S. So, the investors should better check how the spend dollars are controlled when investing in individual big pharma companies. A good control over the expenses is the key for creating very profitable businesses. This is why we wanted to discuss this largely uncovered reality of non-optimally managed spends in the pharma industry. There is an opportunity of billions of dollars in savings. Such a greater discipline could have a great impact on IBB over the upcoming years through higher net profitabilities. M&A’s Are Booming There have been a triple amount of mergers and acquisitions in H1 2015 as compared to H1 2014. We have already seen $221b worth of pharmaceutical deals in H1 2015. This hasn’t been considered yet in the long term industry forecasts. It is a very recent news. These M&A’s will give a further necessary tailwind for IBB. These deals will increase the industry’s key players’ profitability through operational synergies. Risks & Opportunities There are many risks and opportunities and we want to highlight here just a few: Risks Hillary Clinton’s initiatives to push down the healthcare spending in the U.S. Patents expiry on several blockbuster drugs Changing regulatory requirements Rich industry valuations: IBB is trading at a PE of 25.19 and Price/Sales ratio of 7.72 Opportunities Increased focus on Orphan indications with higher margin opportunities Drug price cap removal in China Emerging digital healthcare applications market (drug administration, patient monitoring, etc.) Faster drug development with more modern technologies available in R&D Increase of aging patient populations We believe that by balancing out the risks and opportunities the overall picture is quite positive for the pharma industry. The digital healthcare applications will become a hot market in our opinion. Speaking of the healthcare industry in the wide sense we have covered prior some surgical robotics companies. This is a good example of how the modern technology can revolutionize the market segments and bring benefits to the patients and payers. The readers may have a look on TransEnterix as one example. How To Invest? Surprisingly, we are not holding IBB in our portfolio. Such index is better suited for a passive investor. We prefer to pick individual names and do lots of due diligence on them, that we partially publish at SA articles. We currently have two promising companies in our radar with an imminent share price catalyst in Q1-16. If you want to learn more you can read our articles on Mast Therapeutics and TiGenix. Wake-Up Calls for Two Hidden Gems TiGenix has run up already over 44% since our exclusive article at SA but its valuation is still at a ridiculous level in our opinion. TiGenix (OTC: TGXSF ) already published on 23rd August 2015 that their Phase III study primary end-point was met with the final and full results coming out in Q1-16 for a treatment of perianal fistulas in Crohn’s disease. Their Cx601 allogeneic expanded stem cells drug seems to be very safe as no difference was observed between the drug and placebo groups. The peak sales potential is estimated at $900m and TiGenix trades currently at a market cap of $182m. We think that is making no sense and the share price might have quite a lot of potential to go up with the final Phase III results coming out in Q1-16. We covered Mast Therapeutics (NYSEMKT: MSTX ) at SA on 28th September 2015. It has went up quite a lot after our article was published. It is again an example of a very misunderstood company with a good pipeline drug MST-188 running in late Phase III to treat sickle cell patients. SCD patients have had no proper drug for the past 17 years and this is the first one we expect to arrive on the markets. Both these micro-cap stocks offer a good example of what we look for when picking individual names across the biotechnology sector. We are having long positions with both. Conclusions We believe that IBB is in a secular bull market. This index could still correct lower than the latest 30% drop from the all time high. Eventually, the increased industry revenues towards 2018, recent tripling in M&A activity and a better control over the spend dollars could send IBB to much higher levels. We believe that active investors might be more successful in hand picking individual companies instead of buying IBB. This would go along with a higher risk. Disclaimer: Please do your own research prior to investing and taking investment decisions. This article is provided for informal purposes only and any information mentioned may change at any time without a notice. Please consult your investment advisor for finding a proper allocation for your portfolio that is adjusted with your risk levels and personal situation. Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Picking The Right Silver ETF

Summary Those who consider investing in silver could consider using silver ETFs. The major ones follow the price of silver by stocking up on the precious metal. Other ETFs and ETNs follow silver by using forward contracts. The silver market has seen better days, but some still think silver could recover in the coming years and reach its former glory. The main idea in investing in silver is either for hedging purposes or for those who think silver will go up in the future. Let’s quickly examine the developments in the silver market and the main ETFs representing it. Up to the beginning of 2013, the rising demand for silver was fueled by people and institutions investing in silver via, among other ways, silver ETFs , in part, due to growing fear of a possible spike in inflation driven by the Federal Reserve’s monetary policy – mostly consistent of near zero interest rates and quantitative easing — and the devaluation of the U.S. dollar. These fears haven’t materialized, up to now. In fact, inflation has come down in past year and the U.S. dollar has appreciated against major currencies. The slowly recovery in the U.S. economy, the shift in the Fed’s policy, rise in mine production and little change in silver demand in the industrial sector drove down silver prices in the past few years. Some still expect the silver market to recover in the coming years on account of growing demand for silver in the industrial sector or slower growth in production (on account of the current low prices). Others may need a silver financial instrument to hedge their silver inventory. One way to take a long or short position on silver is via ETFs. Why choose silver-focused ETFs over other available silver instruments? The other possibilities include buying physical silver, silver contracts or silver companies. Buying a stock of physical silver, especially for speculators, may not be the best options. Silver companies are also one way to go long on silver. In this category, investors could pick silver producers such as Pan American Silver (NASDAQ: PAAS ) or silver streaming and royalty companies such as Silver Wheaton (NYSE: SLW ). But there are three issues to consider: These companies may incur risk that isn’t related to the movement in the price of silver such as growing debt and cash flow strain; Silver companies don’t only focus on silver (after all silver is usually a byproduct of other metals); they also have other metals in their portfolio – in most cases gold and copper – and as such bullion companies’ stocks aren’t only impacted by the movement of silver prices. For the most part, silver is strongly correlated to gold, but this relation isn’t consistent over time; The stocks of silver companies are also affected by these companies’ growth in operations (or lack of it); so if they expand their business — stocks tend to rise and vice versa. This is another variable, which isn’t necessarily related to the changes in the price of silver. These issues don’t mean the option of going with a silver company isn’t a good play, but it may not suit your investment needs. With that said, let’s review some of the available silver ETFs for hedges, investors and speculators and the main difference among the ETFs. Investors that have a long term investment horizon wishing to go long on silver or those that need a hedge for the future price of silver — if for example you plan to purchase silver for your business (e.g. for industrial usage) at a later date and need to lock the current price of silver to avoid risk related to fluctuations in the future – could consider the iShares Silver Trust (NYSEARCA: SLV ). This is also the largest traded ETF in this space with a market cap of $4.8 billion. The ETF follows the price of silver by holding the precious metal – as of September 24, the ETF holds 318.2 million ounces. The only caveat is the management fee, which is 0.5%, one needs to pay for holding this ETF. And just in case you were wondering, since this ETF holds physical silver and doesn’t buy future contracts each month – as oil and natural gas ETF tend to do – there is no Contango or Backwardation that lead to roll decay to worry about. Another ETF that follows silver in the same way as SLV is Physical Silver Shares (NYSEARCA: SIVR ), which has a slightly lower management fee of 0.3%. But the ETF is also smaller with a market cap of $280 million and 18.4 million ounces of silver. For speculators with a short term trading horizon (usually daily) and suspect the silver market is heading up may consider ProShares Ultra Silver (NYSEARCA: AGQ ). This ETF follows twice the daily return of the silver. For those who think silver is heading down may use ProShares UltraShort Silver (NYSEARCA: ZSL ), which follows twice the inverse return of silver. Both of these ETFs use silver contracts (forwards) and don’t buy silver bars. Therefore, these ETFs may face roll decay issues related to Contango/Backwardation. These ETFs also have a compounding issue that affects the returns of investments (e.g. if the price of silver rises by 10% in the first day and another 10% the next day, then the total gain is 21% due to compounding). That’s why these investments are mostly for short term investments. It’s also worth mentioning that besides ETFs there are also Exchange traded notes or ETNs . ETNs are structured products issued as senior debt notes. They are based on the future contracts. ETNs are highly volatility, tend to be riskier than ETFs (due to debt risk), and are mostly considered for short term holdings. For a leveraged long silver position, the VelocityShares 3x Long Silver ETN (NASDAQ: USLV ) offers three times the daily return of a silver index (S&P GSCI Silver Index ER). For those seeking to go short over short period of time, VelocityShares 3x Inverse Silver ETN (NASDAQ: DSLV ) is one way to go. Since these ETN are leveraged, they also have compound issues as listed above for ZSL and AGQ as well as Contango/ Backwardation issues. It’s also worth reading these ETNs prospectus to get a better sense of their risks ( pdf ). These ETNs are also very small cap and may include a liquidity issue. The following table summarizes the possible ETFs and ETNs that are currently available with market share and fees. (click to enlarge) Sources: ETFs’ and ETNs’ websites. The above ETFs and ETNs offer an array of investment possibilities for investors, day-traders and hedgers. Based on your needs and outlook, you could utilize the above-mentioned financial instruments. (For more please see: ” Will Higher Physical Demand for Silver Drive Up SLV? “)

Retirement Portfolios – Volatility, Taxes, And Risk

Summary This article refines a previously-presented method for qualifying investment portfolios as suitable for retirement. It uses simple formulas for the effect of taxes on returns and volatilities, which leads to a surprising result: an investor in a higher tax bracket can accept a lower volatility. The method also extends the previous analysis to cover more volatile portfolios, such as those trading XIV and VXX. Introduction A previous article introduced a method for comparing investment portfolios based on back-test results. It considered a recently-retired person who: – Invests an initial amount at the start of retirement, – withdraws a percentage of the initial amount each year, adjusted for inflation, and – holds a portfolio with an expected volatility and return for the duration of their retirement. The previous article showed how to make a go/no-go decision about investing in a portfolio, based on its expected after-tax annualized return, after-tax annualized volatility of returns, and historical inflation. However, back-tests provide pre-tax returns and volatilities, not after-tax figures, and the current level of inflation remains below the mean historical level. To improve the usefulness of the method, this new article shows how to decide whether to invest in a portfolio based on its expected pre-tax returns and volatilities, and based on other-than-historical inflation rates. As before, this article defines risk as a number with direct impact on the retiree, the chance of running out of money during retirement; rather than as a more abstract number, the annualized volatility of returns. A prudent retiree would first seek to reduce risk, the chance of running out of money, to a negligible level. That ensured, the retiree would next seek to increase the portfolio’s balance at the end of retirement to leave a legacy. Simulation method As in the previous article, this analysis uses a Monte Carlo simulation tool at portfoliovisualizer.com to test the risk of a portfolio with a given volatility and return. Table 1 shows the input parameters for the simulation. For each volatility shown in the table, the analysis tried various values of expected return until the simulation output showed a 99% probability of success. This means that at the preset annual withdrawal and volatility settings, 99% of Monte Carlo trials showed a positive balance at the end of retirement. In other words, the retiree did not go broke. The expected return setting that yields 99% probability of success represents the average annualized return necessary throughout retirement to reduce risk to a negligible level at the given settings for annual withdrawal and volatility. Defining negligible risk as 99% probability of success (1% risk) seems appropriate considering the severity of the consequences of running out of money. The simulation tool also provides a median end balance, the retiree’s legacy at the end of retirement in 50% of Monte Carlo trials at the given withdrawal rate and volatility settings, and at the expected return necessary for 99% probability of success at those settings. The simulator shows median end balance discounted for inflation, and therefore expressed in the same dollars as the initial invested amount at the start of retirement. This procedure yielded (volatility, return) pairs at 1% risk of going broke for withdrawing an inflation-adjusted fixed amount annually, equal to 3% of the initial amount. It also provided the median end balance at this volatility, return, and withdrawal rate. Simulation results The simulation tool provided the results in Table 2, where: “Median annual return” = (Median end balance / Initial amount)^(1/30)-1. This gives the median annual rate of return during retirement after inflation and withdrawals at the selected withdrawal rate, the selected volatility, and the rate of return required to reduce risk to 1%. Consider, for example, a portfolio with 15% volatility – similar to the historical volatility of the S&P 500 index. Suppose inflation remains near zero. Table 2 shows that a retiree would need an average annual return of 12% in this portfolio for an acceptable risk of going broke. If the portfolio in fact delivers this 12% return, year after year, then the investor will benefit from a median return after withdrawals of 9%, and the original investment of $1M will rise to a median legacy of $13M at the end of retirement. While this median performance seems more than adequate, remember that there remains a 1% chance of leaving no legacy at all. Each row in Table 2 represents a hypothetical portfolio. Each portfolio has the same 1% risk of going broke, but the portfolios with higher volatility require higher annual returns to reduce risk to that level, and as a consequence, investors benefit from higher median annual returns, and their heirs should benefit from greater legacies. An investor who chooses a higher-volatility portfolio at the same level of risk should expect to experience a jumpier account balance and to leave a greater legacy. Effect of inflation Chart 1, graphed from Table 2, shows how annual return required for 99% success probability increases with volatility. A portfolio with annual return on or above the line has acceptable risk. The lines in Chart 1 can be considered “lines of equal risk,” or in this case, “lines of 1% risk.” The difference between the two lines in Chart 1 is close to the mean historical inflation rate (4.18%). Over the range studied here, the annual return required for 99% success probability can reasonably be estimated as the zero-inflation annual return (lower line in Chart 1), plus the expected inflation rate. For simplicity, the remainder of this article assumes zero inflation, which is close to the situation today. Chart 2, also graphed from Table 2, shows how median annual return (and therefore the investor’s legacy) also increases with volatility. As explained above, each row in Table 2 gives returns for a different volatility, but all rows have the same 1% risk. Similarly, all points on the same line in Chart 2 have the same 1% risk. For these curves, annual return was selected to reduce the worst-case risk to 1% at a given volatility and withdrawal rate. Chart 2 shows that for two portfolios with equal risk, an investor leaves a larger legacy by selecting the portfolio with higher volatility, provided that it delivers the required higher return. Chart 2 also shows, like Chart 1, that the difference between the two curves is close to the mean historical inflation rate (4.18%). Over the range studied here, the median annual return with inflation can reasonably be estimated as the zero-inflation median annual return (lower line in Chart 2), plus the expected inflation rate. Required pre-tax return Until now, the analysis has not considered the effect of taxes. The required return as a function of volatility in Chart 1 must apply to after-tax returns and volatilities, because those are what affect the balance in the retiree’s account. This begs a question, what are the corresponding pre-tax volatilities and returns? Define “Rtn” as the required annual after-tax return for a given after-tax volatility (“Vol”), that is, the annual return required for 99% probability for reaching the end of a 30-year retirement, making 3% annual withdrawals, and assuming zero inflation. At a marginal tax rate “Tax,” the after-tax return: Rtn = (1-Tax)*PreRtn, where PreRtn is the pre-tax return (Equation 1). The after-tax volatility is reduced by the same ratio: Vol = (1-Tax)*PreVol, where PreVol is the pre-tax volatility (Equation 2). Equation 2 holds true for volatility because volatility is a standard deviation (“σ”), and for a random variable X and a constant m: σ(m*X) = m*σ(X). For example, at a tax rate of Tax = 50%, for a portfolio to provide an after-tax volatility of Vol = 15% and an after-tax return of Rtn = 12%, it must have a pre-tax return of PreRtn = Rtn/(1-Tax) = 24%, but it can have a pre-tax volatility as high as PreVol = Vol/(1-Tax) = 30%. Table 3 and Chart 3 show after-tax and pre-tax (volatility, return) pairs for 1% risk. The after-tax volatilities and returns come from Table 2, and the pre-tax volatilities and returns come from applying the simple equations in the preceding paragraph to the after-tax figures. Table 3 and Chart 3 provide pre-tax figures for 50% and 25% marginal tax rates: For example, in Chart 3, portfolio “K” has 45% after-tax volatility, which, from Chart 1, requires 67% after-tax return for 1% risk. With 25% tax, this corresponds to pre-tax volatility of 60% and pre-tax return of 89%. With 50% tax, this corresponds to pre-tax volatility of 90% and pre-tax return of 133%. Back-test results are pre-tax. By the way, these stratospheric volatilities and back-test returns are included here for exceptional strategies, such as those trading derivatives of derivatives (XIV and VXX). Charts 3b and 3c show an expanded view of more usual volatilities and returns. Consequently, Charts 3, 3b, and 3c provide an investor with a way to qualify a portfolio for retirement – it must fall above the line in these charts that corresponds to investors’ marginal tax bracket. If an investor used the lines in the previous article (which were after-tax lines) to qualify a portfolio based on back-tested volatility and return (which are pre-tax figures), this would have been too stringent a qualification test. In effect, the investor would have required a return above the green line in Chart 3, when a return above the yellow or red line would have sufficed. To take inflation into account, the investor needs to shift the curves in Chart 3, 3b, or 3c upward by the expected inflation rate. Chart 3b shows an expanded view of the low-volatility part of Chart 3: Chart 3c shows an expanded view of the midrange of Chart 3: Charts 3, 3b, and 3c show that at a given back-test volatility – which is a pre-tax volatility – the required back-test return – which is a pre-tax return – is lower for a higher tax rate. This non-intuitive result occurs because taxes not only reduce returns, but also reduce volatility. When an investor does poorly, so does the tax collector. Effectively, the tax collector shares the investor’s risk along with the investor’s returns. This analysis has other interesting (and perhaps non-intuitive) consequences: Consider a strategy with back-tested (pre-tax) average annual return of 25% and volatility of 40%. Row F in Table 3 shows that this has acceptable risk for an investor in the 50% tax bracket, but row H in Table 3 shows that it is too risky for an investor in the 25% tax bracket. This investor needs the tax collector to share more of the risk. Now, consider a strategy with a back-tested (pre-tax) average annual return of 20% and volatility of 40%. Rows F and H in Table 3 show that this is too risky for an investor in either tax bracket. However, if that investor keeps 25% of the retirement account in that portfolio and 75% in cash at zero return and zero volatility, the account would have a pre-tax return of 25% * 20% = 5% and a pre-tax volatility of 25% * 40% = 10%. Rows B and C in Table 3 show that this is enough return at this volatility to reduce risk to an acceptable value for an investor in either tax bracket. Discussion and conclusion Investors could use this method to qualify portfolios for retirement investments, based on back-tested returns and volatilities, and taking taxes and inflation into account. The method extends to cover unusually volatile portfolios: even those with 50% volatility can provide acceptable risk after taxes and inflation, provided they maintain acceptable returns. This opens a door toward including non-traditional portfolios – such as those trading VXX and XIV – in a prudent retiree’s account. This method is subject to the classical limitation of back-tests: they do not consistently predict future results. Most investors will want to maintain a mix of qualified portfolios, including a traditional core. Acknowledgement: The author thanks Dr. Toma Hentea for reviewing and clarifying the article. Appendix: Alternative calculations with a pseudo-Sharpe ratio Although Charts 3, 3b, and 3c provide enough information to make a go/no-go decision about investing in a portfolio, there is another method for looking at the data. Both methods reach the same decision in the same situation. For the second method, portfolio back-tests provide not only (volatility, return) pairs, but they also provide a ratio of annualized return to annualized volatility. This is similar to a Sharpe ratio, except it assumes a risk-free return of zero (close to the situation today). Table 4 and Chart 4 show the required return/volatility for 1% risk, using the data from Table 3. Chart 4 shows that the required return/volatility ratio (“pseudo-Sharpe ratio”) for 1% risk increases with volatility over the range studied. It also shows that the pseudo-Sharpe ratio required for a given portfolio (“A” through “L”) does not change with the investor’s tax situation. This follows directly from equations 1 and 2, because volatility and required return change by the same proportion when changing tax situations. Like Chart 3, Chart 4 provides an investor with a method to qualify a portfolio – its pseudo-Sharpe ratio must fall above the curve in Chart 4 for that investor’s marginal tax bracket. Chart 4b provides an expanded view of the lower-volatility part of Chart 4: Charts 4 and 4b show that at a given back-test volatility, the required back-test pseudo-Sharpe ratio for 1% risk is lower for a higher tax rate. As in Charts 3, 3b, and 3c, this occurs because the tax collector shares the investor’s risk along with the investor’s returns.